XGN

XGN

USD

Exagen Inc. Common Stock

$10.770-0.310 (-2.798%)

السعر في الوقت الحقيقي

Healthcare
Diagnostics & Research
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$11.080

الأعلى

$11.500

الأدنى

$10.500

الحجم

1.42M

أساسيات الشركة

القيمة السوقية

237.0M

الصناعة

Diagnostics & Research

البلد

United States

إحصاءات التداول

متوسط الحجم

0.23M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $2.38الحالي $10.770الأعلى $12.23

أخبار ذات صلة

Analyst Upgrades

BTIG Maintains Buy on Exagen, Raises Price Target to $15

BTIG analyst Mark Massaro maintains Exagen with a Buy and raises the price target from $13 to $15.

عرض المزيد
BTIG Maintains Buy on Exagen, Raises Price Target to $15
GlobeNewswire

Exagen Inc. Reports Strong Q3 2025 Results

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent

عرض المزيد
Exagen Inc. Reports Strong Q3 2025 Results
Analyst Upgrades

Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15

Canaccord Genuity analyst Kyle Mikson maintains Exagen with a Buy and raises the price target from $11 to $15.

عرض المزيد
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15
GlobeNewswire

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's

عرض المزيد
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
Analyst Upgrades

BTIG Maintains Buy on Exagen, Raises Price Target to $13

BTIG analyst Mark Massaro maintains Exagen with a Buy and raises the price target from $11 to $13.

عرض المزيد
BTIG Maintains Buy on Exagen, Raises Price Target to $13
GlobeNewswire

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.